Thyrotropin-secreting pituitary adenomas: Biological and molecular features, diagnosis and therapy

Minerva Endocrinologica

Volumn 33, Issue 4, 2008, Pages 329-340

  Losa, M ^a   Fortunato, M ^a   Molteni, L ^a   Pereiti, E ^a   Mortini, P ^a  

^a VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

Hyperthyroidism; Pituitary neoplasm; Thyrotropin

Indexed keywords

ATENOLOL; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR; FIBROBLAST GROWTH FACTOR; GONADOTROPIN; GROWTH HORMONE; IOPANOIC ACID; LIOTHYRONINE; LIOTRIX; PROLACTIN; PROPRANOLOL; PROPYLTHIOURACIL; RADIOACTIVE IODINE; SEX HORMONE BINDING GLOBULIN; SOMATOSTATIN RECEPTOR 5; THIAMAZOLE; THYROID HORMONE RECEPTOR BETA; THYROTROPIN; TRANSCRIPTION FACTOR PIT 1; BIOLOGICAL MARKER; DOPAMINE RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; HUMAN GROWTH HORMONE; SOMATOSTATIN;

CHOLELITHIASIS; DIFFERENTIAL DIAGNOSIS; ETIOLOGY; FAMILIAL DYSALBUMINEMIC HYPERTHYROXINEMIA; FIBROSIS; GOITER; GRAVES DISEASE; GROWTH HORMONE SECRETING CELL; HETEROZYGOTE; HISTOLOGY; HUMAN; HYPERPLASIA; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPERTHYROXINEMIA; HYPOPHYSIS ADENOMA; HYPOTHYROIDISM; INTOXICATION; IRRADIATION; MICROADENOMA; MULTIPLE ENDOCRINE NEOPLASIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE; PROLACTIN SECRETING CELL; RETINOBLASTOMA; REVIEW; SELLA TURCICA; THYROID FUNCTION; THYROID GLAND; THYROIDECTOMY; THYROIDITIS; TUMOR RECURRENCE; TUMOR SUPPRESSOR GENE; ADENOMA; BLOOD; HYPOPHYSIS TUMOR; METABOLISM; SECRETION; TREATMENT OUTCOME;

ADENOMA; BIOLOGICAL MARKERS; DIAGNOSIS, DIFFERENTIAL; DOPAMINE AGONISTS; HUMAN GROWTH HORMONE; HUMANS; HYPERTHYROIDISM; PITUITARY NEOPLASMS; PROLACTIN; SOMATOSTATIN; THYROTROPIN; TREATMENT OUTCOME;

EID: 60849134604     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Jailer JW, Holub DA. Remission of Graves'disease following radiotherapy of a pituitary neoplasm. Am J Med 1960;28:497-500.
2. Hamilton C, Adams LC, Maloof F. Hyperthyroidism due to thyrotropin-producing pituitary chromophobe adenoma. N Engl J Med 1970;283:1077-80.
3. Nicoloff JT, Spencer CA. The use and misuse of the sensitive thyrotropin assay. J Clin Endocrinol Metab 1990;71:553-8.
4. Beck-Peccoz P, Persani L. Thyrotropin (TSH-secreting pituitary tumors: endocrinology, clinical aspects and treatment. In: Landolt AM, Vance ML, Reilly PL, editors. Pituitary adenomas: biology, diagnosis and treatment. London: Churchill Livingstone; 1996. p.139-55.
5. Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumors. Endocr Rev 1996;17:610-38.
6. Ambrosi B, Faglia G, Multicenter Pituitary Tumor Study Group, Lombardia Region. Epidemiology of pituitary tumors. In: Faglia G, Beck-Peccoz P, Ambrosi A, Travaglini P, Spada A, editors. Pituitary adenomas: new trends in basic and clinical research. Amsterdam: Excerpta Medica 1991:159-68.
7. Mindermann T, Wilson CB. Thyrotropin-producing pituitary adenomas. J Neurosurg 1993;79:521-7.
8. Beck-Peccoz P, Persani L. Thyrotropinomas. Endocrinol Metab Clin N Am 2008;37:123-34.
9. Herman V, Fagin J, Gonsky R, Kovacs K, Melmed S. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990;71:1427-33.
10. Alexander JM, Biller BMK, Bikkal H, Zervas NT, Arnold A, Klibanski A. Clinically nonfunctioning pituitary tumours are monoclonal in origin. J Clin Invest 1990;86:336-40. (Pubitemid 20227010)
11. Ma W, Ikeda H, Watabe N, Kanno M, Yoshimoto T. A plurihormonal pituitary tumor of monoclonal origin in a patient with hypothyroidism. Horm Res 2003;59:257-61.
12. Dong Q, Brucker-Davis F, Weintraub BD, Smallridge RC, Carr FE, Battey J et al. Screening of candidate oncogenes in human thyrotroph tumors: absence of activating mutations of the Gaq, Ga11, Gas, or thyrotropin releasing hormone receptor genes. J Clin Endocrinol Metab 1996;81:1134-40.
13. Pellegrini, I, Barlier, A, Gunz, G, Figarella-Branger D, Enjalbert A, Grisoli F et al. Pit-1 gene expression in the human pituitary and pituitary adenomas. J Clin Endocrinol Metab 1994;79:189-96.
14. Asteria C, Anagni M, Persani L, Beck-Peccoz P. Loss of heterozigosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas. J Endocrinol Invest 2001;24:796-801. (Pubitemid 33120974)
15. Ando, S, Sarlis, NJ, Oldfield, EH, Yen, PM. Somatic mutation of TRbeta can cause a defect in negative regulation of TSH in a TSH-secreting pituitary tumour. J Clin Endocrinol Metab 2001;86:5572-6.
16. Ando, S, Sarlis, NJ, Krishnan, J, Feng X, Refetoff S, Zhang MQ et al. Aberrant alternative splicing of thyroid hormone receptor in a TSH-secreting pituitary tumour is a mechanism for hormone resistance. Mol Endocrinol 2001;15:1529-38.
17. Ezzat S, Horvath E, Kovacs K, Smyth HS, Singer W, Asa SL. Basic fibroblast growth factor expression by two prolactin and thyrotropin-producing pituitary adenomas. Endocr Pathol 1995;6:125-34.
18. Filopanti M, Ballarè E, Lania AG, Bondioni S, Verga U, Locatelli M et al. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas. J Endocrinol Invest 2004;27:937-42. (Pubitemid 40124189)
19. Socin HV, Chanson P, Delemer B, Tabarin A, Rohmer V, Mockel J et al. The changing spectrum of TSH-secreting adenomas: diagnosis and management in 43 patients. Eur J Endocrinol 2003;148:433-42.
20. Calle-Pascual AL, Yuste E, Martin P, Aramendi T, Garcia-Maurino ML, Argente J et al. Association of a thyrotropin-secreting pituitary adenoma and a thyroid follicular carcinoma. J Endocrinol Invest 1991;14:499-502.
21. Brucker Davis F, Oldfield E, Skarulis M, Doppman JL. Weintraub BD. Thyrotropin-secreting pituitary tumours: diagnostic criteria, thyroid hormone sensitivity, and treatment outcome in 25 patients followed at the National Institutes of Health. J Clin Endocrinol Metab 1999;84:476-86.
22. Burgess JR, Shepherd JJ, Greenaway TM. Thyrotropinomas in multiple endocrine neoplasia type 1 (MEN-1). Aust NZ J Med 1994;24:740-1.
23. Losa M, Mortini P, Minelli R, Giovanelli M. Coexistence of TSH secreting pituitary adenoma and autoimmune hypothyroidism. J Endocrinol Invest 2006;29:555-9.
24. Beck-Peccoz P, Piscitelli G, Cattaneo MG, Faglia G, White EL, Barlow JW et al. Evaluation of free thyroxine methods in the presence of iodothyronine binding autoantibodies. J Clin Endocrinol Metab 1984;58:736-9. (Pubitemid 14137272)
25. Zweig MH, Csako G, Spero M. Escape from blockade of interfering heterophilic antibodies in a two-site irnmunoradiometric assay for thyrotropin. Clin Chem 1988;34:2589-91.
26. Beck-Peccoz P, Piscitelli G, Medri G, Faglia G. Thyroid test strategý (Letter). Lancet 1985;1:1456.
27. Terzolo M, Orlandi F, Bassetti M, Medri G, Paccotti P, Cortelazzi D et al. Hyperthyroidism due to a pituitary adenoma composed of two different cell types, one secreting alpha-subunit alone and another cosecreting alpha-subunit and thyrotropin. J Clin Endocrinol Metab 1991;72:415-21.
28. Beck-Peccoz P, Persani L, Faglia G. Glycoprotein hormone alpha-subunit in pituitary adenomas. Trends Endocrinol Metab 1992;3:41-5.
29. Refetoff S, Weiss RE, Usala SJ. The syndromes of resistance to thyroid hormone. Endocr Rev 1993;14:348-99.
30. Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab 1996;81:3084-90.
31. Beck-Peccoz P, Roncoroni R, Mariotti S, Medri G, Marcocci C, Brabant G et al. Sex hormone binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): Evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. J Clin Endocrinol Metab 1990;71:19-25. (Pubitemid 20228298)
32. Persani L, Preziati D, Matthews CH, Sartorio A, Chatterjee VK, Beck-Peccoz P. Serum levels of carboxyterminal cross-linked telopeptide of type I collagen (ICTP) in the differential diagnosis of the syndromes of inappropriate secretion of TSH. Clin Endocrinol (Oxf) 1997;47:207-14. (Pubitemid 27359901)
33. Bonomi M, Proverbio MC, Weber G, Chiumello G, Beck-Peccoz P, Persani L. Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations of the TSH beta gene. J Clin Endocrinol Metab 2001; 86:1600-4.
34. Chanson P, Weintraub BD, Harris AG. Octreotide therapy for thyroid stimulating secreting pituitary adenomas. A follow-up of 52 patients. Ann Intern Med 1993;119:236-40.
35. Mannavola D, Persani L, Vannucchi G, Zanardelli M, Fugazzola L, Verga U et al. Different response to chronic somatostatin analogues in patients with central hyperthyroidism. Clin Endocrinol (Oxf) 2005;62:176-81.
36. Cooper DS, Wenig BM. Hyperthyroidism caused by an ectopic TSH-secreting pituitary tumour. Thyroid 1996;6:337-43.
37. Pasquini E, Faustini-Fustini M, Sciarretta V, Saggese D, Roncaroli F, Serra D et al. Ectopic TSH-secreting pituitary adenoma of the vomerosphenoidal junction. Eur J Encocrinol 2003;148:253-7.
38. Molitch ME, Russell EJ. The pituitary "incidentaloma" Ann Intern Med 1990;112:925-31.
39. Losa M, Magnani P, Mortini P, Persani L, Acerno S, Giugni E et al. Indium-111 pentetreotide single-photon emission tomography in patients with TSH-secreting pituitary adenomas: Correlation with the effect of a single administration of octreotide on serum TSH levels. Eur J Nucl Med 1997;24:728-31.
40. Bogazzi F, Manetti L, Tomisti L, Rossi G, Cosci C, Sardella C et al. Thyroid color flow Doppler sonography: an adjunctive tool for differentiating patients with inappropriate thyrotropin (TSH) secretion due to TSH-secreting pituitary adenoma or resistance to thyroid hormone. Thyroid 2006;16:989-95.
41. McCutcheon IE, Weintraub BD, Oldfield EH. Surgical treatment of thyrotropin-secreting pituitary adenomas. J Neurosurg 1990;73:674-83.
42. Sanno N, Teramoto A, Osamura RY. Long-term surgical outcome in 16 patients with thyrotropin pituitary adenoma. J Neurosurg 2000;93:194-200. (Pubitemid 30604859)
43. Ness-Abramof R, Ishay A, Harel G, Sylvetzky N, Baron E, Greenman Y et al. TSH-secreting pituitary adenomas: follow-up of 11 cases and review of the literature. Pituitary 2007;10:307-10.
44. Losa M, Mortini P, Barzaghi R, Gioia L, Giovanelli M. Surgical treatment of PRL-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 2002;87:3180-6.
45. Losa M, Mortini P, Urbaz L, Ribotto P, Castrignanò T, Giovanelli M. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates. J Neurosurg 2006;104:899-906.
46. Kovacs K, Horvath E. Tumours of the pituitary gland. In: Harthrnann WH, Sobin LH, editors. Atlas of tumour pathology, fascicle 21, series 2. Washington DC, USA: Armed Forces Institute of Pathology; 1986.
47. Losa M, Mortini P, Barzaghi R, Ribotto P, Terreni MR, Marzoli SB et al. Early results of surgery in patients with nonfunctioning pituitary adenoma and analysis of the risk of tumor recurrence. J Neurosurg 2008;108:525-32.
48. Losa M, Mortini P, Franzin A, Barzaghi R, Mandelli C, Giovanelli M. Surgical management of thyrotropinsecreting pituitary adenomas. Pituitary 1999;2:127-31.
49. Bochicchio D, Losa M, Buchfelder M. Factors influencing the immediate and late outcome of Cushing's disease treated by transsphenoidal surgery: a retrospective study by the European Cushing's Disease Survey Group. J Clin Endocrinol Metab 1995;80:3114-20.
50. Chanson P, Orgiazzi J, Derome PJ, Bression D, Jedynak CP, Trouillas J et al. Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma. J Clin Endocrinol Metab 1984;59:542-6.
51. Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Longterm management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol 2007;157:39-46.
52. Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A et al. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. J Clin Endocrinol Metab 1992;75:540-6.
53. Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F et al. Evaluation of the treatment of thyrotropinsecreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab 2000;85:1487-91.
54. Comi RJ, Gesundheit N, Murray L, Gorden P, Weintraub BD. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue. N Engl J Med. 1987;317:12-7. (Pubitemid 17093292)
55. Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf) 1994;40:421-8.
56. Gesundheit N, Petrick PA, Nissim M, Dahlberg PA, Doppman JL, Emerson CH et al. Thyrotropin-secreting pituitary adenomas: clinical and biochemical heterogeneity. Case reports and follow-up of nine patients. Ann Intern Med 1989;111:827-35.
57. Gouriotis L, Skarulis M, Brucker-Davis F, Oldfield E, Sarlis N. Effectiveness of long-acting octreotide in suppressing hormonogenesis and tumor growth in thyrotropin-secreting pituitary adenomas: report of two cases. Pituitary 2001;4:135-43.
58. Dhillon KS, Cohan P, Kelly DF, Darwin CH, Iyer KV, Chopra IJ. Treatment of hyperthyroidism associated with thyrotropin-secreting pituitary adenomas with iopanoic acid. J Clin Endocirnol Metab 2004;89:708-11.
59. Gerst, PH, Fildes, J, Baylor, P, Zonszein, J. Long-acting β-adrenergic antagonists as preparation for surgery in thyrotoxicosis. Arch Surg 1986;121:838-40. (Pubitemid 16075813)